NASDAQ$AVXL
Anavex Life Sciences Corp · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fiscal year ended September 30, 2020.
Anavex Life Sciences reported its financial results for the fiscal year ended September 30, 2020, highlighting significant progress across its portfolio, including positive trial results for ANAVEX®2-73 in Rett syndrome and Parkinson's disease dementia.
- Positive, placebo-controlled, U.S. ANAVEX®2-73 (blarcamesine) Rett syndrome trial.
- Positive Parkinson’s disease dementia trial.
- Further progress in Alzheimer’s disease.
- Key milestones expected from multiple programs.
Headline financials
Revenue & EPS history
Anavex · Revenue · Quarterly
$1.12M
Forward guidance
Anavex anticipates key milestones from multiple programs.
Tailwinds
- Data on the ongoing late-stage Rett syndrome trials AVATAR and EXCELLENCE.
- Expanding the clinical biomarker-driven ANAVEX®2-73 rare disease program into additional late-stage studies with high unmet medical need.
- Completing the late stage ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease trial.
- Advancing ANAVEX®2-73 into clinical disease modifying testing in Parkinson’s disease.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+0.4%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+7.1%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+26.0%
Q4 2024
Best reaction
-24.8%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -5.9% | +8.4% | — | |
| Q1 2026 | +6.1% | -4.1% | +13.4% | |
| Q4 2025 | +12.4% | +24.4% | +20.8% | |
| Q3 2025 | -4.9% | -12.4% | -15.6% | |
| Q2 2025 | -1.3% | +1.2% | +24.2% | |
| Q1 2025 | +4.9% | +2.8% | +13.8% | |
| Q4 2024 | +26.0% | +40.3% | +15.8% | |
| Q3 2024 | -5.7% | -2.2% | -13.8% | |
| Q2 2024 | +2.7% | +16.2% | +4.3% | |
| Q1 2024 | -1.7% | +6.0% | -5.9% | |
| Q4 2023 | -4.1% | +7.1% | +40.2% | |
| Q3 2023 | +22.0% | +14.8% | +0.4% | |
| Q2 2023 | +11.3% | +8.2% | +9.9% | |
| Q1 2023 | -1.6% | -5.1% | -12.9% | |
| Q4 2022 | -24.8% | +1.3% | -31.1% | |
| Q3 2022 | +1.9% | +1.7% | -12.9% | |
| Q2 2022 | -3.7% | +13.2% | +12.5% | |
| Q1 2022 | +13.9% | +9.2% | -1.2% | |
| Q4 2021 | +8.2% | +13.7% | +8.5% | |
| Q3 2021 | +8.6% | +7.4% | +3.9% | |
| Q2 2021 | +7.3% | +10.6% | +50.0% | |
| Q1 2021 | -3.4% | -3.3% | +2.6% | |
| Q4 2020 | -4.2% | -6.1% | +4.9% | |
| Q3 2020 | -7.7% | -13.7% | -16.4% | |
| Q2 2020 | +4.5% | +18.9% | +17.1% | |
| Q1 2020 | +5.6% | +12.4% | +7.9% | |
| Q4 2019 | -2.0% | +0.4% | +23.8% | |
| Q3 2019 | +5.5% | -0.4% | +12.2% | |
| Q2 2019 | -1.3% | -1.3% | -4.2% | |
| Q1 2019 | +13.0% | +19.2% | +36.1% | |
| Q4 2018 | -3.8% | -10.4% | -5.2% | |
| Q3 2018 | -5.5% | -3.8% | -7.6% | |
| Q2 2018 | -0.9% | +4.5% | +70.0% | |
| Q1 2018 | -8.4% | -11.2% | +4.6% | |
| Q4 2017 | -13.3% | -14.6% | -10.3% | |
| Q3 2017 | -6.3% | -10.0% | +22.1% | |
| Q2 2017 | -3.6% | -0.5% | -1.2% | |
| Q1 2017 | +5.7% | +12.2% | +3.1% | |
| Q4 2016 | -2.8% | -6.2% | -6.2% | |
| Q3 2016 | +22.1% | +9.6% | -0.7% | |
| Q2 2016 | -10.9% | — | — | |
| Q1 2016 | -20.0% | — | — | |
| Q4 2015 | -21.8% | — | — | |
| Q3 2015 | +13.9% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +17.6% | — | — | |
| Q3 2014 | +4.2% | — | — | |
| Q2 2014 | -8.3% | — | — | |
| Q1 2014 | -9.7% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q2 2013 | +8.2% | — | — | |
| Q1 2013 | +5.6% | — | — | |
| Q4 2012 | -1.3% | — | — | |
| Q3 2012 | -17.6% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +14.4% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -1.6% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q2 2010 | +1.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro